Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2007
[Inhibition of angiogenesis in the anterior chamber of the eye].
Аннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bock F, König Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C
Аннотация
BACKGROUND: Recent years have seen tremendous progress in our understanding of the mechanisms of neovascular diseases of the eye. Antiangiogenic treatment options are now widely used in the management of age-related maculopathy (AMD) and diabetic retinopathy. The aim of this article is to highlight some novel methods of local antiangiogenic treatment of the cornea and conjunctiva and in the anterior chamber of the eye.
METHODS: The study took the form of a literature review (PUBMED) and a review of the authors' own data.
RESULTS: Initial experience with novel inhibitors of angiogenesis, especially bevacizumab, used locally on cornea and conjunctiva is promising. Intracameral injections of VEGF inhibitors can be used to ameliorate neovascular glaucoma.
CONCLUSION: Novel antiangiogenic drugs are available for topical use in the anterior segment of the eye (as off-label use) and will improve the management of neovascular diseases affecting cornea and conjunctiva and in the anterior chamber of the eye.
METHODS: The study took the form of a literature review (PUBMED) and a review of the authors' own data.
RESULTS: Initial experience with novel inhibitors of angiogenesis, especially bevacizumab, used locally on cornea and conjunctiva is promising. Intracameral injections of VEGF inhibitors can be used to ameliorate neovascular glaucoma.
CONCLUSION: Novel antiangiogenic drugs are available for topical use in the anterior segment of the eye (as off-label use) and will improve the management of neovascular diseases affecting cornea and conjunctiva and in the anterior chamber of the eye.